
Tarun Handa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/84818/publications.pdf Version: 2024-02-01



Τλριίνι Ηλνισλ

#	Article	IF	CITATIONS
1	A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2012, 69, 148-173.	1.4	166
2	Critical practical aspects in the application of liquid chromatography–mass spectrometric studies for the characterization of impurities and degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2014, 87, 191-217.	1.4	77
3	Stress degradation studies on lornoxicam using LC, LC–MS/TOF and LC–MSn. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 538-545.	1.4	24
4	Characterization of a new degradation product of nifedipine formed on catalysis by atenolol: A typical case of alteration of degradation pathway of one drug by another. Journal of Pharmaceutical and Biomedical Analysis, 2014, 89, 6-17.	1.4	22
5	Successful characterization of degradation products of drugs using LC-MS tools: Application to piroxicam and meloxicam. Analytical Methods, 2011, 3, 2864.	1.3	21
6	ICH guidance in practice: Degradation behaviour of oseltamivir phosphate under stress conditions. Journal of Pharmaceutical and Biomedical Analysis, 2012, 62, 48-60.	1.4	17
7	Study of the forced degradation behavior of prasugrel hydrochloride by liquid chromatography with mass spectrometry and liquid chromatography with NMR detection and prediction of the toxicity of the characterized degradation products. Journal of Separation Science, 2015, 38, 2995-3005.	1.3	13
8	Molecular insight into atypical instability behavior of fixed-dose combination containing amlodipine besylate and losartan potassium. Journal of Pharmaceutical and Biomedical Analysis, 2017, 136, 66-80.	1.4	6
9	Explanation through density functional theory of the unanticipated loss of CO ₂ and differences in mass fragmentation profiles of ritonavir and its rCYP3A4-mediated metabolites. Journal of Mass Spectrometry, 2014, 49, 452-467.	0.7	0